Results 131 to 140 of about 16,336,802 (316)
The therapeutic oxymoron: exploring the mechanisms of open-label placebo
, 2023 Placebos have emancipated themselves from earlier, often unethical or merely research- based practices, toward an open and thereby ethical administration. Despite a plethora of efficacy studies and nearly two decades of empirical research on open-label placebos (OLPs), little to nothing is known about the circumstances under which they realize their ...
openaire +1 more source
Advanced Science, EarlyView.This graphical abstract presents gut microbial cross‐feeding through a Mechanism–Technology–Application framework. It summarizes major resource‐transfer modes, the experimental and computational tools used to establish causality, and potential interventions involving dietary substrates, live biotherapeutic products, and engineered microbes.
Chuankai Sun +7 more
wiley +1 more source
Effects of Open-Label Placebos on Visual Food Cue Reactivity in Children and Adolescents
ChildrenBackground: A high level of food cue reactivity (FCR) is a risk factor for overeating and weight gain. This randomized trial investigated whether open-label placebos (OLPs: placebos honestly administered) can reduce FCR (reported appetite) in children ...
Anne Schienle +4 more
doaj +1 more source
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
Advanced Science, EarlyView.This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li +11 more
wiley +1 more source
Applied Economic Perspectives and Policy, EarlyView.ABSTRACT Rational actors constantly incorporate information into their decision‐making behavior. Since there is often a time lag between the announcement of a policy and its implementation, an important question arises: when do rational actors incorporate new information into their market behavior, at the announcement or at the implementation of a ...
Tim Ölkers, Oliver Mußhoff
wiley +1 more source
Data of the allergic diary demonstrate improvement of the open-label placebo group over time.
, 2018 Data of the allergic diary demonstrate improvement of the open-label placebo group over time.
Benjamin Berstecher (4919128) +2 more
core +1 more source
Botulinum Toxin as Preventive Treatment for Migraine: A Randomized Double-Blind Study [PDF]
, 2009 Aim: To determine if botulinum toxin type A (BoNT-A) injections can reduce the frequency and severity of migraines. Methods: Patients (n = 127) were randomized to receive placebo or two doses of BoNT-A (Dysport (R)). The primary endpoint was reduction in
Toelle, Thomas +13 more
core +1 more source
The Antidiabetic Potential of Alpha‐Mangostin: A Review of Preclinical and Clinical Evidence
AgriFood: Journal of Agricultural Products for Food, EarlyView.Alpha‐mangostin is a compound from the pericarp of Garcinia mangostana. The antidiabetic effects of alpha‐mangostin include enhancing insulin secretion, improving glucose uptake through GLUT receptor upregulation, reducing oxidative stress and inflammation, promoting wound healing, reducing HbA1C, reducing HOMA‐IR index, and decreased mRNA expressions ...
Oliver Dean John +4 more
wiley +1 more source
Journal of the Formosan Medical AssociationBackground/purpose: Acute hepatic porphyrias (AHP) are rare genetic disorders associated with acute neurovisceral attacks and chronic symptoms.
Ming-Jen Lee +4 more
doaj +1 more source
Investigating the role of motivation in open-label placebo responses [PDF]
Placebo effects occur when an individual receives an inactive treatment that should be unable to provide therapeutic benefits but still demonstrates meaningful improvements in health.
Worthington, Joshua
core